Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial

Seyyedeh Maryam Afshani, Reihaneh Mirhassani, Hamed Hosseini, Reihaneh Hosseini, Afsaneh Tehranian, Reza Malekzadeh, Afshin Ostovar, Amir Hossein Abdolghaffari, Mohammad Amin Ghobadi, Behnaz Hedayatjoo, Delara Hazegh Fetratjoo, Zahra Rezagholi, AmirHossein Anari, Ashraf Moini

Open source

DOI: 10.1097/cej.0000000000000753
Published: 2022-03-29
Container: European Journal of Cancer Prevention
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/cej.0000000000000753,
  title = {Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial},
  author = {Seyyedeh Maryam Afshani and Reihaneh Mirhassani and Hamed Hosseini and Reihaneh Hosseini and Afsaneh Tehranian and Reza Malekzadeh and Afshin Ostovar and Amir Hossein Abdolghaffari and Mohammad Amin Ghobadi and Behnaz Hedayatjoo and Delara Hazegh Fetratjoo and Zahra Rezagholi and AmirHossein Anari and Ashraf Moini},
  year = {2022},
  journal = {European Journal of Cancer Prevention},
  doi = {10.1097/cej.0000000000000753},
  url = {https://doi.org/10.1097/cej.0000000000000753}
}

RIS

TY  - JOUR
TI  - Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial
AU  - Seyyedeh Maryam Afshani
AU  - Reihaneh Mirhassani
AU  - Hamed Hosseini
AU  - Reihaneh Hosseini
AU  - Afsaneh Tehranian
AU  - Reza Malekzadeh
AU  - Afshin Ostovar
AU  - Amir Hossein Abdolghaffari
AU  - Mohammad Amin Ghobadi
AU  - Behnaz Hedayatjoo
AU  - Delara Hazegh Fetratjoo
AU  - Zahra Rezagholi
AU  - AmirHossein Anari
AU  - Ashraf Moini
PY  - 2022
JO  - European Journal of Cancer Prevention
DO  - 10.1097/cej.0000000000000753
UR  - https://doi.org/10.1097/cej.0000000000000753
ER  -

APA

Afshani, S. M., Mirhassani, R., Hosseini, H., Hosseini, R., Tehranian, A., Malekzadeh, R., Ostovar, A., Abdolghaffari, A. H., Ghobadi, M. A., Hedayatjoo, B., Fetratjoo, D. H., Rezagholi, Z., Anari, A., & Moini, A. (2022). Immunogenicity and safety of a bivalent, adjuvant system 04–adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15–25: a randomized, double-blind, phase III, noninferiority clinical trial. European Journal of Cancer Prevention. https://doi.org/10.1097/cej.0000000000000753

Source records

crossref · retrieved 2026-09-26T01:31:36.510Z